Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma.

Front Pharmacol · 2025 · PMC12263411 · PMID 40672372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Nimutuzumab as a humanized EGFR mAb with less toxicity showed a trend benefit for ORR and OS in the second-line treatment of advanced ESCC ( Wang et al., 2024 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.